Summarized by Masters of Longevity from Longevity Technology.
A Miami longevity biotech won a nine-month NYU Stern life sciences accelerator spot while progressing from preclinical work toward starting human trials.
Key Takeaways
- Longevity startups, which often spend years in the lab before they ever see a patient, may love one even more.
- This is a business-development program, and being picked says something about how the company’s plan looks to a panel of outside evaluators.
- SenoMune is a senolytic immunotherapy, designed to restore the immune system’s natural ability to recognize and eliminate senescent cells.
